India has approved its first dengue vaccine after the country’s drug regulator granted market authorisation to Takeda Biopharmaceuticals’ QDENGA. The decision marks an important development in dengue prevention in a country that regularly faces outbreaks of the mosquito-borne disease.
Takeda, the Japan-based drugmaker, said the vaccine has received clearance for use in India. A key feature highlighted in the approval is that QDENGA can be given whether or not a person has had dengue before, removing the need for pre-vaccination screening.
That point is significant because pre-vaccination testing can complicate access and slow wider use. A vaccine that does not require checking prior dengue exposure could make deployment simpler if health authorities choose to incorporate it into broader prevention efforts.
The approval also places India among the markets where QDENGA is now authorised, as public health systems continue to look for stronger tools to reduce severe illness and ease pressure during dengue seasons. Further details on availability and rollout are expected to shape how quickly the vaccine reaches eligible people.
